Clinical Research Directory
Browse clinical research sites, groups, and studies.
Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study
Sponsor: University of Alabama at Birmingham
Summary
Psychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the underlying pathologies in those with poor treatment response using complimentary brain imaging modalities.
Official title: Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study in Medication-naïve First Episode Psychosis Patients
Key Details
Gender
All
Age Range
17 Years - 35 Years
Study Type
OBSERVATIONAL
Enrollment
156
Start Date
2018-04-01
Completion Date
2026-12-31
Last Updated
2026-01-12
Healthy Volunteers
No
Conditions
Interventions
Patients with psychosis will be treated with known antipsychotic medication
Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.
Locations (1)
Sparks Center
Birmingham, Alabama, United States